Puma Biotechnology (PBYI) PT Lowered to $27 at Cowen

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. ISRG
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to Puma Biotechnology (PBYI) PT Lowered to $27 at Cowen

Puma Biotech (PBYI) Announces Data from Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer

June 4, 2019 11:11 AM EDT

Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that results from the Phase III NALA trial of PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease) in the setting of metastatic disease, were presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial, was presented as an oral presentation by Adam... More